BrainBox Solutions
BrainBox Solutions develops AI-enabled, multi-modality diagnostic and prognostic tools for mild traumatic brain injury that integrate blood-based biomarker panels, digital neurocognitive assessments, and point-of-care device technology. The company's platform is validated through large, multi-site clinical trials covering adults, geriatrics, and pediatrics, with an emphasis on evidence-based evaluation, risk stratification, and real-world clinical adoption. Research partnerships, grant funding, and a strong intellectual property portfolio support their objective of providing diagnostic and prognostic solutions for brain injury across diverse care settings and patient populations.
Industries
Nr. of Employees
small (1-50)
BrainBox Solutions
737 N Fifth St, Suite 304, Richmond, VA 23219, United States
Patents
Protein biomarker indicators of neurological injury and/or disease and methods of use thereof
2026-09-15 • US-12736547-B2
View DetailsMethods and compositions for diagnosing brain injury or neurodegeneration
2026-02-24 • US-12560619-B2
View DetailsBiomarker levels and neuroimaging for detecting, monitoring and treating brain injury or trauma
2025-11-04 • US-12461112-B2
View DetailsCirculating biomarker levels for diagnosis and risk-stratification of traumatic brain injury
2025-04-01 • US-12265091-B2
View DetailsMethods and compositions for diagnosing brain injury or neurodegeneration
2024-07-16 • US-12038446-B2
View DetailsProtein biomarker indicators of neurological injury and/or disease and methods of use thereof
2024-05-21 • US-11988676-B2
View Details
Protein biomarker indicators of neurological injury and/or disease and methods of use thereof
2026-09-15 • US-12736547-B2
View DetailsMethods and compositions for diagnosing brain injury or neurodegeneration
2026-02-24 • US-12560619-B2
View DetailsBiomarker levels and neuroimaging for detecting, monitoring and treating brain injury or trauma
2025-11-04 • US-12461112-B2
View DetailsCirculating biomarker levels for diagnosis and risk-stratification of traumatic brain injury
2025-04-01 • US-12265091-B2
View DetailsMethods and compositions for diagnosing brain injury or neurodegeneration
2024-07-16 • US-12038446-B2
View DetailsProtein biomarker indicators of neurological injury and/or disease and methods of use thereof
2024-05-21 • US-11988676-B2
View DetailsProducts
Integrated system combining multi-marker blood biomarker analysis, digital neurocognitive assessment, and AI-based scoring to objectively diagnose mild traumatic brain injury and predict risk for persistent symptoms across clinical settings and age groups.
Integrated system combining multi-marker blood biomarker analysis, digital neurocognitive assessment, and AI-based scoring to objectively diagnose mild traumatic brain injury and predict risk for persistent symptoms across clinical settings and age groups.
Expertise Areas
- Traumatic brain injury diagnostics
- Multi-marker assay development
- Clinical trial management
- Digital neurocognitive assessment
Key Technologies
- Multiplex blood biomarker analysis
- Digital neurocognitive testing
- Point-of-care diagnostic platforms
- Single-molecule detection technology
Key People
Chief Operating Officer, Global Supply Chain Management
Chief Technology Officer/Advisor
Chief Scientific Officer
Controller
Director of Data Analytics
Chief Operating Officer, Global Supply Chain Management
Chief Technology Officer/Advisor
Chief Scientific Officer
Controller
Director of Data Analytics
News & Updates
Received Breakthrough Device Designation for objective concussion diagnostic and prognostic test.
Awarded research grant funding from the NFL-GE Head Health Challenge, NIH, and Virginia Catalyst to advance concussion diagnostics.
Secured Series B investments to support regulatory clearance and launch of diagnostic/prognostic technology.
Analysis of 1,000 patients in the pivotal trial identifies predictive factors for persistent symptoms following mild traumatic brain injury.
Publication details methodology and objectives of the HeadSMART II study for objective diagnosis and prognosis of acute traumatic brain injury.
Peer-reviewed publication discussing clinical characteristics and outcomes of mild traumatic brain injury.
Received Breakthrough Device Designation for objective concussion diagnostic and prognostic test.
Awarded research grant funding from the NFL-GE Head Health Challenge, NIH, and Virginia Catalyst to advance concussion diagnostics.
Secured Series B investments to support regulatory clearance and launch of diagnostic/prognostic technology.
Analysis of 1,000 patients in the pivotal trial identifies predictive factors for persistent symptoms following mild traumatic brain injury.
Publication details methodology and objectives of the HeadSMART II study for objective diagnosis and prognosis of acute traumatic brain injury.
Peer-reviewed publication discussing clinical characteristics and outcomes of mild traumatic brain injury.